Document Detail


Tumour resistance to cisplatin: a modelling approach.
MedLine Citation:
PMID:  15715425     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Although chemotherapy has revolutionized the treatment of haematological tumours, in many common solid tumours the success has been limited. Some of the reasons for the limitations are: the timing of drug delivery, resistance to the drug, repopulation between cycles of chemotherapy and the lack of complete understanding of the pharmacokinetics and pharmacodynamics of a specific agent. Cisplatin is among the most effective cytotoxic agents used in head and neck cancer treatments. When modelling cisplatin as a single agent, the properties of cisplatin only have to be taken into account, reducing the number of assumptions that are considered in the generalized chemotherapy models. The aim of the present paper is to model the biological effect of cisplatin and to simulate the consequence of cisplatin resistance on tumour control. The 'treated' tumour is a squamous cell carcinoma of the head and neck, previously grown by computer-based Monte Carlo techniques. The model maintained the biological constitution of a tumour through the generation of stem cells, proliferating cells and non-proliferating cells. Cell kinetic parameters (mean cell cycle time, cell loss factor, thymidine labelling index) were also consistent with the literature. A sensitivity study on the contribution of various mechanisms leading to drug resistance is undertaken. To quantify the extent of drug resistance, the cisplatin resistance factor (CRF) is defined as the ratio between the number of surviving cells of the resistant population and the number of surviving cells of the sensitive population, determined after the same treatment time. It is shown that there is a supra-linear dependence of CRF on the percentage of cisplatin-DNA adducts formed, and a sigmoid-like dependence between CRF and the percentage of cells killed in resistant tumours. Drug resistance is shown to be a cumulative process which eventually can overcome tumour regression leading to treatment failure.
Authors:
L Marcu; E Bezak; I Olver; T van Doorn
Related Documents :
12036455 - Dexamethasone-resistant human pre-b leukemia 697 cell line evolving elevation of intrac...
8607825 - Role of ceramide in stimulation of the transcription of cytosolic phospholipase a2 and ...
3855485 - Uptake of methotrexate linked to polyclonal and monoclonal antimelanoma antibodies by a...
10930805 - Modulation of drug resistance by alpha-tubulin in paclitaxel-resistant human lung cance...
6715265 - Gap junctions in the stria vascularis and effects of ethacrynic acid.
20840735 - Inhibition of the interactions between eosinophil cationic protein and airway epithelia...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Physics in medicine and biology     Volume:  50     ISSN:  0031-9155     ISO Abbreviation:  Phys Med Biol     Publication Date:  2005 Jan 
Date Detail:
Created Date:  2005-02-17     Completed Date:  2005-06-07     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0401220     Medline TA:  Phys Med Biol     Country:  England    
Other Details:
Languages:  eng     Pagination:  93-102     Citation Subset:  IM    
Affiliation:
School of Chemistry and Physics, University of Adelaide, North Terrace, SA 5000, Australia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Agents / pharmacology
Cell Proliferation
Cell Survival
Cisplatin / chemistry*,  pharmacology*
DNA Adducts / chemistry*
Drug Resistance*
Drug Resistance, Neoplasm*
Humans
Kinetics
Models, Statistical
Monte Carlo Method
Neoplasms / drug therapy*,  pathology
Normal Distribution
Stem Cells / cytology
Time Factors
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 0/DNA Adducts; 0/cisplatin-DNA adduct; 15663-27-1/Cisplatin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Human epithelial cells increase their rigidity with ageing in vitro: direct measurements.
Next Document:  Quantitative analysis of patient-specific dosimetric IMRT verification.